Giant cell reparative granuloma

Summary

Giant cell reparative granuloma (MONDO:0006770) is a disease and 1 clinical trial. A subtype of bone giant cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	giant cell reparative granuloma
Mondo ID	MONDO:0006770
EFO	EFO:1000950
MeSH	D006101
Orphanet	696078
DOID	DOID:1866
NCIT	C121893
SNOMED CT	15350006
UMLS	C0162375
MedGen	102385
GARD	0024470
Is cancer (heuristic)	no

Also known as: central giant cell (reparative) granuloma · central giant cell granuloma · GCLSB · giant cell lesion of small bones

Disease family

This is a subtype of bone giant cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone sarcoma › bone giant cell tumor › giant cell reparative granuloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Calcitonin	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02358304	PHASE2	COMPLETED	Efficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell Granuloma